Literature DB >> 21142277

Calibrating models in economic evaluation: a seven-step approach.

Tazio Vanni1, Jonathan Karnon, Jason Madan, Richard G White, W John Edmunds, Anna M Foss, Rosa Legood.   

Abstract

In economic evaluation, mathematical models have a central role as a way of integrating all the relevant information about a disease and health interventions, in order to estimate costs and consequences over an extended time horizon. Models are based on scientific knowledge of disease (which is likely to change over time), simplifying assumptions and input parameters with different levels of uncertainty; therefore, it is sensible to explore the consistency of model predictions with observational data. Calibration is a useful tool for estimating uncertain parameters, as well as more accurately defining model uncertainty (particularly with respect to the representation of correlations between parameters). Calibration involves the comparison of model outputs (e.g. disease prevalence rates) with empirical data, leading to the identification of model parameter values that achieve a good fit. This article provides guidance on the theoretical underpinnings of different calibration methods. The calibration process is divided into seven steps and different potential methods at each step are discussed, focusing on the particular features of disease models in economic evaluation. The seven steps are (i) Which parameters should be varied in the calibration process? (ii) Which calibration targets should be used? (iii) What measure of goodness of fit should be used? (iv) What parameter search strategy should be used? (v) What determines acceptable goodness-of-fit parameter sets (convergence criteria)? (vi) What determines the termination of the calibration process (stopping rule)? (vii) How should the model calibration results and economic parameters be integrated? The lack of standards in calibrating disease models in economic evaluation can undermine the credibility of calibration methods. In order to avoid the scepticism regarding calibration, we ought to unify the way we approach the problems and report the methods used, and continue to investigate different methods.

Mesh:

Year:  2011        PMID: 21142277     DOI: 10.2165/11584600-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  38 in total

1.  Could the CARE-SHAKTI intervention for injecting drug users be maintaining the low HIV prevalence in Dhaka, Bangladesh?

Authors:  Anna M Foss; Charlotte H Watts; Peter Vickerman; Tasnim Azim; Lorna Guinness; Munir Ahmed; Andrea Rodericks; Smarajit Jana
Journal:  Addiction       Date:  2007-01       Impact factor: 6.526

2.  Bayesian inference of hospital-acquired infectious diseases and control measures given imperfect surveillance data.

Authors:  M L Forrester; A N Pettitt; G J Gibson
Journal:  Biostatistics       Date:  2006-08-22       Impact factor: 5.899

Review 3.  Confronting models with data.

Authors:  Ben S Cooper
Journal:  J Hosp Infect       Date:  2007-06       Impact factor: 3.926

4.  The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?

Authors:  Rob Anderson; Marion Haas; Marian Shanahan
Journal:  Aust N Z J Public Health       Date:  2008-02       Impact factor: 2.939

Review 5.  Artificial neural networks: opening the black box.

Authors:  J E Dayhoff; J M DeLeo
Journal:  Cancer       Date:  2001-04-15       Impact factor: 6.860

6.  The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods.

Authors:  Jeanne Mandelblatt; Clyde B Schechter; William Lawrence; Bin Yi; Jennifer Cullen
Journal:  J Natl Cancer Inst Monogr       Date:  2006

7.  Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales.

Authors:  Caroline L Trotter; W John Edmunds
Journal:  BMJ       Date:  2002-04-06

8.  The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.

Authors:  S J Goldie; M C Weinstein; K M Kuntz; K A Freedberg
Journal:  Ann Intern Med       Date:  1999-01-19       Impact factor: 25.391

9.  Multiparameter calibration of a natural history model of cervical cancer.

Authors:  Jane J Kim; Karen M Kuntz; Natasha K Stout; Salaheddin Mahmud; Luisa L Villa; Eduardo L Franco; Sue J Goldie
Journal:  Am J Epidemiol       Date:  2007-05-25       Impact factor: 4.897

10.  Cost-effectiveness of HPV 16, 18 vaccination in Brazil.

Authors:  Sue J Goldie; Jane J Kim; Katie Kobus; Jeremy D Goldhaber-Fiebert; Joshua Salomon; Meredith K H O'shea; F Xavier Bosch; Silvia de Sanjosé; Eduardo L Franco
Journal:  Vaccine       Date:  2007-06-15       Impact factor: 3.641

View more
  51 in total

1.  Incorporating calibrated model parameters into sensitivity analyses: deterministic and probabilistic approaches.

Authors:  Douglas C A Taylor; Vivek Pawar; Denise T Kruzikas; Kristen E Gilmore; Myrlene Sanon; Milton C Weinstein
Journal:  Pharmacoeconomics       Date:  2012-02-01       Impact factor: 4.981

2.  Calibrating models in economic evaluation: a comparison of alternative measures of goodness of fit, parameter search strategies and convergence criteria.

Authors:  Jonathan Karnon; Tazio Vanni
Journal:  Pharmacoeconomics       Date:  2011-01       Impact factor: 4.981

3.  Calibration of complex models through Bayesian evidence synthesis: a demonstration and tutorial.

Authors:  Christopher H Jackson; Mark Jit; Linda D Sharples; Daniela De Angelis
Journal:  Med Decis Making       Date:  2013-07-25       Impact factor: 2.583

4.  Mechanical thrombectomy in patients with acute ischemic stroke: a cost-utility analysis.

Authors:  Xuanqian Xie; Anna Lambrinos; Brian Chan; Irfan A Dhalla; Timo Krings; Leanne K Casaubon; Cheemun Lum; Nancy Sikich; Aditya Bharatha; Vitor Mendes Pereira; Grant Stotts; Gustavo Saposnik; Christina O'Callaghan; Linda Kelloway; Michael D Hill
Journal:  CMAJ Open       Date:  2016-06-16

5.  Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.

Authors:  Ankur Pandya; Stephen Sy; Sylvia Cho; Milton C Weinstein; Thomas A Gaziano
Journal:  JAMA       Date:  2015-07-14       Impact factor: 56.272

6.  Performance of a mathematical model to forecast lives saved from HIV treatment expansion in resource-limited settings.

Authors:  April D Kimmel; Daniel W Fitzgerald; Jean W Pape; Bruce R Schackman
Journal:  Med Decis Making       Date:  2014-10-20       Impact factor: 2.583

7.  Economic evaluations with agent-based modelling: an introduction.

Authors:  Jagpreet Chhatwal; Tianhua He
Journal:  Pharmacoeconomics       Date:  2015-05       Impact factor: 4.981

8.  Bayesian Methods for Calibrating Health Policy Models: A Tutorial.

Authors:  Nicolas A Menzies; Djøra I Soeteman; Ankur Pandya; Jane J Kim
Journal:  Pharmacoeconomics       Date:  2017-06       Impact factor: 4.981

9.  Cost-effectiveness analysis of selective first-line use of biologics for unresectable RAS wild-type left-sided metastatic colorectal cancer.

Authors:  W W L Wong; M Zargar; S R Berry; Y J Ko; M Riesco-Martínez; K K W Chan
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

10.  Multiobjective Calibration of Disease Simulation Models Using Gaussian Processes.

Authors:  Aditya Sai; Carolina Vivas-Valencia; Thomas F Imperiale; Nan Kong
Journal:  Med Decis Making       Date:  2019-08-02       Impact factor: 2.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.